What do systematic reviews say?

IVIg vs placebo

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Moxifloxacin vs amoxicillin‐clavulanate

It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.3, 1.31]
  1 study · 54 participants
  Very low

Moxifloxacin vs amoxicillin‐clavulanate

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 54 participants
  Very low

Moxifloxacin vs amoxicillin‐clavulanate

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

AB103 vs placebo

It is very uncertain whether AB103 changes mortality compared with placebo (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.34 [0.05, 2.16]
  1 study · 43 participants
  Very low

AB103 vs placebo

It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 1.49 [0.52, 4.27]
  1 study · 43 participants
  Very low

AB103 vs placebo

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

AB103 vs placebo

The review found no eligible studies for this question.

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

IVIg vs placebo

Intravenous immunoglobulin showed no clear difference in mortality compared with placebo (low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 1.17 [0.42, 3.23]
  1 study · 100 participants
  Low

Imiquimod vs vehicle

Imiquimod showed no clear difference in short‐term clinical cure (up to 3 months after start of treatment)… compared with vehicle (moderate certainty).

• Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
  RR 1.33 [0.92, 1.93]
  4 studies · 850 participants
  Moderate

Imiquimod vs vehicle

Imiquimod showed no clear difference in medium‐term clinical cure (after 3 months and up to 6 months after… compared with vehicle (moderate certainty).

• Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
  RR 0.88 [0.67, 1.14]
  2 studies · 702 participants
  Moderate

Imiquimod vs vehicle

Imiquimod showed no clear difference in long‐term clinical cure (beyond 6 months after start of treatment)… compared with vehicle (moderate certainty).

• Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.79, 1.17]
  2 studies · 702 participants
  Moderate

Imiquimod vs vehicle

Imiquimod showed no clear difference in short‐term clinical improvement (up to 3 months after start of… compared with vehicle (high certainty).

• Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
  RR 1.14 [0.89, 1.47]
  4 studies · 850 participants
  High

Imiquimod vs vehicle

Imiquimod showed no clear difference in any adverse effect compared with vehicle (high certainty).

• Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
  RR 0.97 [0.88, 1.07]
  3 studies · 827 participants
  High

Imiquimod vs vehicle

Imiquimod probably leads to higher application site reactions compared with vehicle (moderate certainty).

• Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
  RR 1.41 [1.13, 1.77]
  3 studies · 827 participants
  Moderate

Imiquimod vs vehicle

Imiquimod probably leads to higher severe application site reactions compared with vehicle (moderate certainty).

• Interventions for cutaneous molluscum contagiosum 2017 · Cochrane Headline outcomes only
  RR 4.33 [1.16, 16.19]
  3 studies · 827 participants
  Moderate

Paromomycin ointment vs vehicle

It is very uncertain whether paromomycin ointment changes microbiological or histopathological cure of skin lesions compared with vehicle (very low certainty).

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  RR 1.03 [0.88, 1.2]
  2 studies · 383 participants
  Very low

Paromomycin ointment vs vehicle

The review found no eligible studies for this question.

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Paromomycin ointment vs vehicle

It is very uncertain whether paromomycin ointment changes percentage of participants with complete cure compared with vehicle (very low certainty).

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  RR 1 [0.86, 1.17]
  2 studies · 383 participants
  Very low

Paromomycin ointment vs vehicle

It is very uncertain whether paromomycin ointment changes adverse effects Skin/local reactions compared with vehicle (very low certainty).

• Interventions for Old World cutaneous leishmaniasis 2017 · Cochrane Headline outcomes only
  RR 1.42 [0.67, 3.01]
  4 studies · 713 participants
  Very low